SEGMENTED INFORMATION (Tables)

3 Months Ended

Mar. 31, 2021

SEGMENTED INFORMATION

Schedule of segmented revenue and net profit/(loss)

	BioNexus Malaysia			Chemrex			Total			Consolidated with BGLC
	Three months ended March 31, 2021
REVENUE	$	97,363		$	3,351,796		$	3,449,159		$	3,449,159
COST OF REVENUE		(67,707	)		(2,798,887	)		(2,866,594	)		(2,866,594	)
GROSS PROFIT		29,656			552,909			582,565			582,565
OTHER INCOME		763			61,625			62,388			62,388
OPERATING EXPENSES
General and administrative		(22,511	)		(233,152	)		(255,663	)		(302,851	)
FINANCE COSTS		(1,207	)		(2,151	)		(3,358	)		(3,358	)
PROFIT BEFORE TAX		6,701			379,231			385,932			338,744
Tax expense:		0			0			0			0
NET PROFIT	$	6,701		$	379,231		$	385,932		$	338,744

	BioNexus Malaysia			Chemrex			Total			Consolidated with BGLC
	Three months ended March 31, 2020
REVENUE	$	0		$	3,070,026		$	3,070,026		$	3,070,026
COST OF REVENUE		(12,992	)		(2,401,727	)		(2,414,719	)		(2,414,719	)
GROSS (LOSS)/PROFIT		(12,992	)		668,299			655,307			655,307
OTHER INCOME		4,745			741,896			746,641			746,641
OPERATING EXPENSES
General and administrative		(20,149	)		(290,635	)		(310,784	)		(328,418	)
FINANCE COSTS		(1,063	)		(1,963	)		(3,026	)		(3,026	)
(LOSS)/PROFIT BEFORE TAX		(29,459	)		1,117,597			1,088,138			1,070,504
Tax expense:		(860	)		0			(860	)		(860	)
NET (LOSS)/PROFIT	$	(30,319	)	$	1,117,597		$	1,087,278		$	1,069,644

	As Of March 31, 2021 and December 31, 2020
	Total Assets				Total Liabilities
	2021		2020		2021		2020
Bionexus (M)	$	816,893	$	902,552	$	711,549	$	800,610
Chemrex		8,894,730		9,008,245		2,976,336		3,283,814
TOTAL		9,711,623		9,910,797		3,687,885		4,084,424